GLP-1 Medications for Obesity and Type 2 Diabetes May Influence Brain Function
Popular medications used to treat obesity and type 2 diabetes, such as semaglutide (Ozempic) and tirzepatide (Mounjaro), are being investigated for potential effects beyond weight loss and blood sugar control. Researchers from the University of Gothenburg and the University of Copenhagen reviewed existing scientific evidence, suggesting these GLP-1 medications may influence biological processes related to brain function, raising questions about their ability to preserve memory and thinking abilities. While animal studies indicate GLP-1 drugs can affect learning and memory, human research has yielded less consistent results. Observational studies of patient health records have shown an association between GLP-1 treatment and a reduced risk of dementia in individuals with type 2 diabetes. However, clinical trials, such as Novo Nordisk's EVOKE and EVOKE+ studies, found that semaglutide did not slow the progression of early Alzheimer's disease, despite affecting some Alzheimer's-related biological markers. Res...